{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:29:36Z","timestamp":1784172576944,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.chest.2023.10.024","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T01:56:11Z","timestamp":1698458171000},"page":"356-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Management of Critically Ill Patients Receiving Medications for Opioid Use Disorder"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-9921","authenticated-orcid":false,"given":"Brian L.","family":"Erstad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4384-7012","authenticated-orcid":false,"given":"Melody J.","family":"Glenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.chest.2023.10.024_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229174","article-title":"National U.S. time-trends in opioid use disorder hospitalizations and associated healthcare utilization and mortality","volume":"15","author":"Singh","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.chest.2023.10.024_bib2","author":"Linker"},{"key":"10.1016\/j.chest.2023.10.024_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jcrc.2019.06.032","article-title":"A\u00a0national survey of approaches to manage the ICU patient with opioid use disorder","volume":"54","author":"Reichheld","year":"2019","journal-title":"J\u00a0Crit Care"},{"issue":"2S","key":"10.1016\/j.chest.2023.10.024_bib4","first-page":"1","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","year":"2020","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.chest.2023.10.024_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The Clinical Opiate Withdrawal Scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J\u00a0Psychoactive Drugs"},{"issue":"6","key":"10.1016\/j.chest.2023.10.024_bib8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: an overview","volume":"33","author":"Shulman","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.chest.2023.10.024_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916654146","article-title":"Characterization of methadone as a \u03b2-arrestin-biased \u03bc-opioid receptor agonist","volume":"12","author":"Doi","year":"2016","journal-title":"Mol Pain"},{"issue":"14","key":"10.1016\/j.chest.2023.10.024_bib11","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.chest.2023.10.024_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am J Addict"},{"issue":"5","key":"10.1016\/j.chest.2023.10.024_bib13","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/cpt.2717","article-title":"Identifying clinically relevant drug-drug interactions with methadone and buprenorphine: A translational approach to signal detection","volume":"112","author":"Miano","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.chest.2023.10.024_bib14","first-page":"CD008939","article-title":"QTc interval screening for cardiac risk in methadone treatment of opioid dependence","volume":"6","author":"Pani","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.chest.2023.10.024_bib15","first-page":"234","article-title":"Transferring patients from methadone to buprenorphine: the feasibility and evaluation of practice guidelines","volume":"12","author":"Lintzeris","year":"2018","journal-title":"J\u00a0Addict Med"},{"issue":"5","key":"10.1016\/j.chest.2023.10.024_bib16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1521-0391.2012.00262.x","article-title":"Treatment of buprenorphine precipitated withdrawal: a case report","volume":"21","author":"Jutras-Aswad","year":"2012","journal-title":"Am J Addict"},{"issue":"6","key":"10.1016\/j.chest.2023.10.024_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","article-title":"Methadone\u2014metabolism, pharmacokinetics and interactions","volume":"50","author":"Ferrari","year":"2004","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.chest.2023.10.024_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40122-019-00143-6","article-title":"A\u00a0narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain","volume":"9","author":"Gudin","year":"2020","journal-title":"Pain Ther"},{"issue":"2","key":"10.1016\/j.chest.2023.10.024_bib19","first-page":"93","article-title":"Buprenorphine pharmacology review: update on transmucosal and long-acting formulations","volume":"13","author":"Coe","year":"2019","journal-title":"J\u00a0Addict Med"},{"issue":"7","key":"10.1016\/j.chest.2023.10.024_bib21","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.chest.2023.10.024_bib22","series-title":"Zubsolv (buprenorphine and naloxone sublingual tablets) [package insert]","year":"2023"},{"key":"10.1016\/j.chest.2023.10.024_bib23","series-title":"Suboxone\u00ae (buprenorphine and naloxone) sublingual film [package insert]","year":"2023"},{"issue":"11","key":"10.1016\/j.chest.2023.10.024_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241362","article-title":"Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block","volume":"15","author":"Tran","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.chest.2023.10.024_bib25","series-title":"Butrans (buprenorphine patch, extended release) [package insert]","author":"Purdue Pharma","year":"2019"},{"issue":"5","key":"10.1016\/j.chest.2023.10.024_bib26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/ajad.13193","article-title":"Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanyl","volume":"30","author":"Mariani","year":"2021","journal-title":"Am J Addict"},{"key":"10.1016\/j.chest.2023.10.024_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106394","article-title":"Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder","volume":"105","author":"Seval","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"10.1016\/j.chest.2023.10.024_bib28","first-page":"e232","article-title":"Inpatient low-dose transitions from full agonist opioids including methadone onto long-acting depot buprenorphine: case series from a multicenter clinical trial","volume":"17","author":"Seval","year":"2023","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.chest.2023.10.024_bib29","series-title":"Sublocade (buprenorphine extended-release) injection, for subcutaneous use [package insert]","year":"2023"},{"key":"10.1016\/j.chest.2023.10.024_bib30","series-title":"Brixadi (buprenorphine) extended-release injection for subcutaneous use [package insert]","year":"2023"},{"issue":"9","key":"10.1016\/j.chest.2023.10.024_bib31","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/pm\/pnaa020","article-title":"Perioperative continuation of buprenorphine at low-moderate doses was associated with lower postoperative pain scores and decreased outpatient opioid dispensing compared with buprenorphine discontinuation","volume":"21","author":"Quaye","year":"2020","journal-title":"Pain Med"},{"issue":"1","key":"10.1016\/j.chest.2023.10.024_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1213\/ANE.0000000000001346","article-title":"Sublingual administration of drugs: be cautious","volume":"123","author":"Kiran","year":"2016","journal-title":"Anesth Analg"},{"key":"10.1016\/j.chest.2023.10.024_bib33","series-title":"Buprenex (buprenorphine hydrochloride injection) [package insert]","year":"2022"},{"issue":"1","key":"10.1016\/j.chest.2023.10.024_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03639045.2019.1706552","article-title":"Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data","volume":"46","author":"Hjelmstr\u00f6m","year":"2020","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.chest.2023.10.024_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109541","article-title":"Development of an intravenous low-dose buprenorphine initiation protocol","volume":"237","author":"Jablonski","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1016\/j.chest.2023.10.024_bib36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/01.jcp.0000138766.15858.c6","article-title":"Effects of high-dose intravenous buprenorphine in experienced opioid abusers","volume":"24","author":"Umbricht","year":"2004","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.chest.2023.10.024_bib37","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/ijnp\/pyy071","article-title":"Making Sense of pharmacology: Inverse agonism and functional selectivity","volume":"21","author":"Berg","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.chest.2023.10.024_bib38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41386-022-01416-z","article-title":"Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade","volume":"48","author":"Tr\u00f8stheim","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"10118","key":"10.1016\/j.chest.2023.10.024_bib39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"10401","key":"10.1016\/j.chest.2023.10.024_bib40","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0140-6736(23)00113-7","article-title":"Misclassification of overdose events in the X:BOT study","volume":"402","author":"Dasgupta","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.chest.2023.10.024_bib41","series-title":"Vivitrol (naltrexone for extended-release injectable suspension), for intramuscular use [package insert]","year":"2022"},{"key":"10.1016\/j.chest.2023.10.024_bib42","series-title":"Naltrexone for opioid use disorders: a review of clinical effectiveness, cost-effectiveness, and guidelines","author":"Jahagirdar","year":"2017"},{"issue":"3","key":"10.1016\/j.chest.2023.10.024_bib43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0014-2999(89)90539-6","article-title":"Chronic opioid antagonist treatment: assessment of receptor upregulation","volume":"170","author":"Yoburn","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.chest.2023.10.024_bib44","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fphar.2014.00280","article-title":"Opioid receptor desensitization: mechanisms and its link to tolerance","volume":"5","author":"Allouche","year":"2014","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.chest.2023.10.024_bib45","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/AJP.0b013e31816b2f43","article-title":"Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations","volume":"24","author":"Chu","year":"2008","journal-title":"Clin J Pain"},{"key":"10.1016\/j.chest.2023.10.024_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108869","article-title":"Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32\u00a0mg of hydromorphone","volume":"226","author":"Agin-Liebes","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"10.1016\/j.chest.2023.10.024_bib47","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1097\/CCM.0000000000003299","article-title":"Clinical practice guidelines for the prevention and management of pain, agitation\/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU","volume":"46","author":"Devlin","year":"2018","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2023.10.024_bib48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/healthcare11010034","article-title":"Acute pain management pearls: a focused review for the hospital clinician","volume":"11","author":"Hyland","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"10.1016\/j.chest.2023.10.024_bib49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13054-023-04491-w","article-title":"Prevalence and risk factors of significant persistent pain symptoms after critical care illness: a prospective multicentric study","volume":"27","author":"Bourdiol","year":"2023","journal-title":"Crit Care"},{"issue":"5","key":"10.1016\/j.chest.2023.10.024_bib50","first-page":"CD002024","article-title":"Alpha2-adrenergic agonists for the management of opioid withdrawal","volume":"2016","author":"Gowing","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.chest.2023.10.024_bib51","first-page":"CD002025","article-title":"Buprenorphine for managing opioid withdrawal","volume":"2","author":"Gowing","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.chest.2023.10.024_bib52","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/archpsyc.1985.01790340041006","article-title":"Clonidine in morphine withdrawal. Differential effects on signs and symptoms","volume":"42","author":"Jasinski","year":"1985","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.chest.2023.10.024_bib53","series-title":"Lucemyra\u2122 (lofexidine) tablets, for oral use [package insert]","year":"2018"},{"issue":"10241","key":"10.1016\/j.chest.2023.10.024_bib54","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(20)30852-7","article-title":"New directions in the treatment of opioid withdrawal","volume":"395","author":"Srivastava","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.chest.2023.10.024_bib55","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s13181-014-0430-3","article-title":"Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?","volume":"10","author":"Albertson","year":"2014","journal-title":"J\u00a0Med Toxicol"},{"issue":"4","key":"10.1016\/j.chest.2023.10.024_bib56","first-page":"483","article-title":"Synergistic effect of ketamine and buprenorphine observed in the treatment of buprenorphine precipitated opioid withdrawal in a patient with fentanyl use","volume":"16","author":"Hailozian","year":"2022","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.chest.2023.10.024_bib57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-244X-3-16","article-title":"Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]","volume":"3","author":"Assadi","year":"2003","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.chest.2023.10.024_bib58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fpsyt.2019.00228","article-title":"Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review","volume":"10","author":"Ahmed","year":"2019","journal-title":"Front Psychiatry"},{"issue":"3","key":"10.1016\/j.chest.2023.10.024_bib59","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jemermed.2019.12.034","article-title":"Management of opioid use disorder in the emergency department: a white paper prepared for the American Academy of Emergency Medicine","volume":"58","author":"Strayer","year":"2020","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.chest.2023.10.024_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.110891","article-title":"Trazodone for sleep disturbance in opioid dependent patients maintained on buprenorphine: a double blind, placebo-controlled trial","volume":"250","author":"Goyal","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.chest.2023.10.024_bib61","series-title":"Evidence Brief: Managing Acute Pain in Patients with Opioid Use Disorder on Medication-Assisted Treatment","author":"Veazie","year":"2019"},{"issue":"10","key":"10.1016\/j.chest.2023.10.024_bib62","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/rapm-2021-103007","article-title":"Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel","volume":"46","author":"Kohan","year":"2021","journal-title":"Reg Anesth Pain Med"},{"issue":"4","key":"10.1016\/j.chest.2023.10.024_bib63","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1526-4637.2002.02047.x","article-title":"Methadone reincarnated: novel clinical applications with related concerns","volume":"3","author":"Fishman","year":"2002","journal-title":"Pain Med"},{"issue":"6","key":"10.1016\/j.chest.2023.10.024_bib65","first-page":"377","article-title":"Safe methadone induction and stabilization: report of an expert panel","volume":"7","author":"Baxter","year":"2013","journal-title":"J\u00a0Addict Med"},{"issue":"5","key":"10.1016\/j.chest.2023.10.024_bib66","first-page":"408","article-title":"Initiation and rapid titration of methadone in an acute care setting for the treatment of opioid use disorder: a case report","volume":"13","author":"Hemmons","year":"2019","journal-title":"J\u00a0Addict Med"},{"issue":"6","key":"10.1016\/j.chest.2023.10.024_bib67","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/add.15799","article-title":"Low- and very low-dose buprenorphine induction: new(ish) uses for an old(ish) medication?","volume":"117","author":"Weimer","year":"2022","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.chest.2023.10.024_bib68","first-page":"399","article-title":"Low dose initiation of buprenorphine: a narrative review and practical approach","volume":"16","author":"Cohen","year":"2022","journal-title":"J\u00a0Addict Med"},{"issue":"5","key":"10.1016\/j.chest.2023.10.024_bib69","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ADM.0000000000001189","article-title":"Evidence on buprenorphine dose limits: a review","volume":"17","author":"Grande","year":"2023","journal-title":"J Addict Med"},{"issue":"6","key":"10.1016\/j.chest.2023.10.024_bib70","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids","volume":"17","author":"Weimer","year":"2023","journal-title":"J Addict Med"},{"key":"10.1016\/j.chest.2023.10.024_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1052113","article-title":"Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder","volume":"13","author":"Laffont","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223056696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223056696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T02:05:35Z","timestamp":1737597935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369223056696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0012369223056696"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2023.10.024","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Critically Ill Patients Receiving Medications for Opioid Use Disorder","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2023.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}